<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841139</url>
  </required_header>
  <id_info>
    <org_study_id>2004-004965-14</org_study_id>
    <secondary_id>MREC: 06/Q2707/7</secondary_id>
    <secondary_id>R&amp;D Birminham: RRK 2785</secondary_id>
    <secondary_id>MHRA: 21761/0003/001</secondary_id>
    <secondary_id>2004-004965-14</secondary_id>
    <nct_id>NCT00841139</nct_id>
  </id_info>
  <brief_title>Metabolic Manipulation in Chronic Heart Failure</brief_title>
  <official_title>Metabolic Manipulation in Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Birmingham NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventional measures used for the treatment of chronic heart failure act predominantly by
      reducing the work performed by the heart. In a recent study, the investigators showed that
      one drug (perhexiline) substantially improved symptoms and cardiac function in heart failure.
      The investigators wish to confirm these findings and test whether or not this drug acts by
      altering the heart's energy source thus augmenting the energetic status and work efficiency
      of the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perhexiline maleate is an antianginal agent which increases the efficiency of energy
      production by shifting substrate utilisation from free fatty acids towards glucose. We showed
      that perhexiline therapy was highly effective in improving exercise capacity, symptoms and
      cardiac function in patients with systolic heart failure of both ischaemic and non ischaemic
      aetiology. Perhexiline acts by inhibiting both carnitine palmitoyl transferase-1 (CPT-1) and
      CPT-2, which are key enzymes in mitochondrial free fatty acid uptake. This leads to increased
      myocardial glucose substrate utilization. Further we wish to ascertain whether or not this
      drug improves cardiac energetics and efficiency by altering substrate utilization. In this
      proposal we will assess the cardiac function (by cardiac Magnetic Resonance Imaging MRI),
      cardiac energetic status (by cardiac Magnetic Resonance Spectroscopy MRS), cardiac efficiency
      (via pressure-volume loops) and substrate utilization (via left and right heart
      catheterization), following one month of perhexiline therapy or placebo in patients with
      symptomatic idiopathic dilated cardiomyopathy on optimal conventional heart failure
      medications. An interim analysis is planned after 20 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac energetics as demonstrated by resting myocardial PCr/ATP ratio from cardiac MRS</measure>
    <time_frame>1 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mechanical efficiency (external work / MVO2)</measure>
    <time_frame>1 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory quotient</measure>
    <time_frame>1 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Perhexiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>perhexiline 100mg bd for 1 month duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo one tablet bd for 1 month duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perhexiline</intervention_name>
    <description>100mg o bd</description>
    <arm_group_label>Perhexiline</arm_group_label>
    <other_name>Pexsig</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet bd</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Optimally-medicated idiopathic dilated cardiomyopathy

          -  Symptomatic ( NYHA IIb-III)

          -  Impaired left ventricular systolic function (EF &lt; 40%)

        Exclusion Criteria:

          -  Abnormal liver function tests (defined as above twice the upper limit of normal (ULN))

          -  Concomitant use of Amiodarone , Quinidine , Haloperidol or Selective serotonin (5HT)
             uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6
             enzyme.

          -  Pre-existing evidence of peripheral neuropathy.

          -  Women of childbearing potential.

          -  Patients with implantable cardiac devices (or any other contraindication to MRI).

          -  Obesity ( BMI &gt; 32)

          -  Obstructive sleep apnea syndrome

          -  Patients with known hypersensitivity to perhexiline

          -  Patients with impaired renal function (Creatinine &gt; 250 Âµmol/L)

          -  Valvular heart disease defined as more than moderate valvular stenosis or
             regurgitation.

          -  Atrial Fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Frenneaux, MBBS MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger M Beadle, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Brimingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>November 25, 2011</last_update_submitted>
  <last_update_submitted_qc>November 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Birmingham NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Roger Beadle</investigator_full_name>
    <investigator_title>Research Fellow to Professor MP Frenneaux</investigator_title>
  </responsible_party>
  <keyword>perhexiline</keyword>
  <keyword>idiopathic dilated cardiomyopathy</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>cardiac energetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perhexiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

